Clinical implications of chirality and stereochemistry in psychopharmacology

Journal of Psychosocial Nursing and Mental Health Services

Volumn 47, Issue 8, 2009, Pages 17-21

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL STIMULANT AGENT; NARCOTIC ANALGESIC AGENT;

CHEMISTRY; HUMAN; MENTAL DISEASE; PSYCHOPHARMACOLOGY; REVIEW; STEREOISOMERISM;

ANALGESICS, OPIOID; ANTIDEPRESSIVE AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; MENTAL DISORDERS; PSYCHOPHARMACOLOGY; STEREOISOMERISM; SYMPATHOMIMETICS;

EID: 70350444855     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20090722-01     Document Type: Article

References (26)

1. Baumann, P., & Eap, C.B. (2001). Enantiomeric antidepressant drugs should be considered on individual merit. Human Psychopharmacology: Clinical and Experimental, 16(Suppl. 2), S85-S92.
2. Burke, D., & Henderson, D.J. (2002). Chirality: A blueprint for the future. British Journal of Anaesthesia, 88, 563-576.
3. Burke, W.J., & Kratochvil, C.J. (2002). Stereoisomers in psychiatry: The case of escitalopram. Primary Care Companion to the Journal of Clinical Psychiatry, 4, 20-24.
4. Carroll, L. (1897). Through the looking-glass, and what Alice found there. Philadelphia: Henry Altemus.
5. Cintas, P. (2007). Tracing the origins and evolution of chirality and handedness in chemical language. Angewandte Chemie International Edition, 46, 4016-4024.
6. Coutts, R.T., & Baker, G.B. (1989). Implications of chirality and geometric isomerism in some psychoactive drugs and their metabolites. Chirality, 1, 99-120.
7. Denke, M.A. (2005). Diet, lifestyle, and nonstatin trials: Review of time to benefit. American Journal of Cardiology, 96(5A), 3F-10F.
8. Dent, J. (2003). Review article: Pharmacology of esomeprazole and comparisons with omeprazole. Alimentary Pharmacology and Therapeutics, 17(Suppl. 1), 5-9.
9. Drew, C.D., Knight, G.T., Hughes, D.T., & Bush, M. (1978). Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the car-diovascular and respiratory systems in man. British Journal of Clinical Pharmacology, 6, 221-225.
10. Frampton, J.E., & Foster, R.H. (2006). Pregabalin: In the treatment of generalized anxiety disorder. CNS Drugs, 20, 685-693.
11. Hall, J.G. (2003). Twinning. Lancet, 362, 735-743.
12. Heal, D.J., & Pierce, D.M. (2006). Methylphenidate and its isomers: Their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs, 20, 713-738.
13. Howland, R.H. (2008). Lisdexamfetamine: A prodrug stimulant for ADHD. Journal of Psychosocial Nursing and Mental Health Services, 46(8), 19-22.
14. Lane, R.M., & Baker, G.B. (1999). Chirality and drugs used in psychiatry: Nice to know or need to know? Cellular and Molecular Neurobiology, 19, 355-372.
15. Levin, M., & Mercola, M. (1998). The compulsion of chirality: Toward an understanding of left-right asymmetry. Genes and Development, 12, 763-769.
16. Patrick, K.S., & Markowitz, J.S. (1997). Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Human Psychopharmacology: Clinical and Experimental, 12, 527-546.
17. Paul, R., Schaaff, N., Padberg, F., Moller, H.J., & Frodl, T. (2007). Comparison of racemic ketamine and S-ketamine in treatment-resistant depression: Report of two cases. World Journal of Biological Psychiatry. First published online October 29, 2007. doi: 10.1080/15622 970701714370
18. Sánchez, C., Bøgesø, K.P., Ebert, B., Reines, E.H., & Braestrup, C. (2004). Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology, 174, 163-176.
19. Sell, C.S. (2004). Scent through the looking glass. Chemistry and Biodiversity, 1, 1899-1920.
20. Shah, R.R. (2002). The significance of QT interval in drug development. British Journal of Clinical Pharmacology, 54, 188-202.
21. Steiner, T.J., Ahmed, F., Findley, L.J., MacGregor, E.A., & Wilkinson, M. (1998). S-fluoxetine in the prophylaxis of migraine: A phase II double-blind randomized placebo-controlled study. Cephalalgia, 18, 283-286.
22. Temussi, P.A. (2009). Sweet, bitter and umami receptors: A complex relationship. Trends in Biochemical Sciences, 34, 296-302.
23. Uehlinger, C., Crettol, S., Chassot, P., Brocard, M., Koeb, L., Brawand-Amey, M., et al. (2007). Increased (R)-methadone plasma concentrations by quetiapine in cytrochrome P450s and ABCB1 genotyped patients. Journal of Clinical Psychopharmacology, 27, 273-278.
24. Waldeck, B. (2003). Three-dimensional pharmacology, a subject ranging from ignorance to overstatements. Pharmacology and Toxicology, 93, 203-210.
25. Wisor, J.P., Dement, W.C., Aimone, L., Williams, M., & Bozyczko-Coyne, D. (2006). Armodafinil, the R-enantiomer of modafinil: Wake-promoting effects and pharmacokinetic profile in the rat. Pharmacology, Biochemistry, and Behavior, 85, 492-499.
26. Yasar, S., Gaál, J., Panlilio, L.V., Justinova, Z., Molnár, S.V., Redhi, G.H., et al. (2006). A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a secondorder schedule in squirrel monkeys. Psychopharmacology, 183, 413-421.